Pharmaceutical Executive-08-19-2008

Tacked on to Genentech's press statement about its rejection of Roche's offer, the biotech firm announced the formation of a program to address employee concerns.

The case for preemption gets shot down in Texas, but holds up in yet another Medtronic suit in Minnesota.

Margaret McGlynn, Merck's head of vaccines, expounded yesterday on the state of the company's vaccine program, including campaign strategies, product development, and a new reimbursement program for doctors.